IGC Pharma Secures North American Patent, Advances Phase 2 Enrollment to 70%
The Canadian Intellectual Property Office has granted a Notice of Allowance for patent No. 3,095,729, securing composition protection for IGC-AD1’s low-dose THC formulation in North America. This decision bolsters the exclusivity of its Phase 2 CALMA agitation trial as enrollment reaches approximately 70%.
1. North American Patent Allowance
The Canadian Intellectual Property Office issued a Notice of Allowance for patent No. 3,095,729, granting composition protection for IGC-AD1’s proprietary low-dose THC combination therapy across Canada and the US, reinforcing the drug’s IP coverage.
2. Phase 2 CALMA Enrollment Progress
Approximately 70% of the planned enrollment in the randomized, double-blind, placebo-controlled CALMA trial has been completed, with full enrollment and subsequent database lock identified as the upcoming milestones for data readout preparation.
3. Strategic and Commercial Implications
Securing broad composition protection enhances IGC-AD1’s long-term market exclusivity and supports its commercial differentiation as a multi-target cannabinoid-based therapy for Alzheimer’s agitation, potentially strengthening IGC Pharma’s valuation prospects.